Twice-daily radiation linked to better quality of life

A cancer treatment schedule that asks patients to return twice a day is associated with a more favorable long-term pattern in patient reports. In the 544-patient NRG-LU005 trial of limited-stage small-cell lung cancer, twice-daily radiation was associated with a more favorable quality-of-life trajectory than once-daily radiation after chemoradiation.

The result comes with a boundary that matters: patients were not randomly assigned to the two radiation schedules. The analysis therefore found an association, not proof that twice-daily treatment produced the difference. The association remained after adjustment for patient characteristics, but other factors may still have contributed. Dr. Benjamin Movsas was the QOL chair of the study and is co-medical director of Henry Ford Cancer in Michigan.

NRG-LU005 itself tested something else. Patients received standard concurrent chemoradiation, with thoracic radiation delivered at 45 Gy twice daily or 66 Gy daily, and were randomized to receive or not receive concurrent and adjuvant atezolizumab, an immunotherapy drug. Adding the drug did not improve overall survival. The analysis used validated patient surveys covering well-being, general health and fatigue.

The surveys show the shape of recovery rather than a single snapshot. Quality of life declined during chemoradiation, then improved at three months and remained stable or exceeded baseline from six to 21 months after treatment. Survey compliance was above 85% at baseline and later stabilized at 60%–68%; healthier patients with better performance scores and lung function were more likely to complete them.

It is not yet a prescription to switch radiation schedules: the non-randomized comparison leaves the causal question open. The trial also found fewer clinically meaningful declines in one measure in the immunotherapy arm—25% versus 38% at 21 months—but that observation was also influenced by who remained able to complete assessments.